{"id":5634,"date":"2024-01-18T09:41:56","date_gmt":"2024-01-18T15:41:56","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5634"},"modified":"2025-06-27T11:24:42","modified_gmt":"2025-06-27T16:24:42","slug":"nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","title":{"rendered":"Nanoscope Therapeutics \u304c\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u7528 MCO-010 \u306b\u95a2\u3059\u308b\u898f\u5236\u6700\u65b0\u60c5\u5831\u3092\u63d0\u4f9b"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<ul type=\"disc\">\n<li><strong><i>FDA\u3068EU\u898f\u5236\u5f53\u5c40\u306f\u3001\u8996\u529b\u304c\u5f31\u8996\u306e\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u60a3\u8005\u306e\u6cbb\u7642\u306b\u304a\u3051\u308bMCO-010\u306e\u6709\u52b9\u6027\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306e\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u6a5f\u80fd\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3068\u3044\u3046\u4e00\u8cab\u3057\u305f\u30a2\u30c9\u30d0\u30a4\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u308b<\/i><\/strong><\/li>\n<li><strong><i>\u898f\u5236\u5f53\u5c40\u304b\u3089\u306e\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u306b\u3088\u308a\u3001\u7c73\u56fd\u304a\u3088\u3073\u305d\u306e\u4ed6\u306e\u56fd\u3067\u306e\u627f\u8a8d\u306b\u81f3\u308b\u6f5c\u5728\u7684\u306a\u9053\u7b4b\u304c\u660e\u78ba\u306b\u306a\u308a\u307e\u3059\u3002\u00a0<span class=\"xn-location\">\u30e8\u30fc\u30ed\u30c3\u30d1<\/span>\u00a0RP \u306e MCO-010 \u7528\u3002 Nanoscope \u306f\u5373\u6642\u5b9f\u884c\u306b\u5411\u3051\u3066\u6e96\u5099\u4e2d<\/i><\/strong><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">2024 \u5e74 1 \u6708 18 \u65e5<\/span><\/span> \u2014\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4071016-1&h=2117084114&u=https%3A%2F%2Fnanostherapeutics.com%2F&a=Nanoscope+Therapeutics+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>, \u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u304a\u3088\u3073\u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08AMD\uff09\u306b\u5bfe\u3059\u308b\u907a\u4f1d\u5b50\u6cbb\u7642\u85ac\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u5f8c\u671f\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b[\u4f01\u696d\u540d]\u306f\u672c\u65e5\u3001\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08FDA\uff09\u3068\u306e\u6700\u8fd1\u306e\u898f\u5236\u5354\u8b70\u304a\u3088\u3073\u30a2\u30a4\u30b9\u30e9\u30f3\u30c9\u533b\u85ac\u54c1\u5e81\uff08IMA\uff09\u3068\u306e\u79d1\u5b66\u7684\u52a9\u8a00\u4f1a\u8b70\u3092\u53d7\u3051\u3066\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u6cbb\u7642\u85acMCO-010\u306e\u898f\u5236\u7d4c\u8def\u306b\u95a2\u3059\u308b\u6700\u65b0\u60c5\u5831\u3092\u63d0\u4f9b\u3057\u307e\u3057\u305f\u3002.<\/p>\n<p>FDA \u3068\u306e\u30bf\u30a4\u30d7 B \u30d5\u30a7\u30fc\u30ba 2 \u7d42\u4e86\u306b\u95a2\u3059\u308b\u751f\u7523\u7684\u306a\u8b70\u8ad6\u306b\u95a2\u9023\u3057\u3066\u3001Nanoscope \u306f\u3001\u9032\u884c\u6027 RP \u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u306b\u304a\u3051\u308b MCO-010 \u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u95a2\u3059\u308b\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u3092\u53d7\u3051\u53d6\u308a\u307e\u3057\u305f\u3002 FDA\u306f\u3001\u5f31\u8996\u60a3\u8005\u306e\u8996\u529b\u6e2c\u5b9a\u306b\u304a\u3051\u308b\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u304b\u3089\u306e\u5909\u5316\u306f\u3001\u9069\u5207\u304b\u3064\u3088\u304f\u7ba1\u7406\u3055\u308c\u305f\u7814\u7a76\u306b\u304a\u3051\u308b\u9069\u5207\u306a\u4e00\u6b21\u6709\u52b9\u6027\u8a55\u4fa1\u3068\u306a\u308a\u3001BLA\u306e\u627f\u8a8d\u3092\u88cf\u4ed8\u3051\u308b\u6709\u76ca\u6027\u306e\u5b9f\u8cea\u7684\u306a\u8a3c\u62e0\u3092\u63d0\u4f9b\u3067\u304d\u308b\u3068\u8ff0\u3079\u305f\u3002 MCO-010 \u306f\u3001FDA \u304b\u3089\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u3068\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u306e\u4e21\u65b9\u306e\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>Nanoscope \u306f\u3001MCO-010 \u306e\u627f\u8a8d\u30d7\u30ed\u30bb\u30b9\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001IMA \u3068\u306e\u79d1\u5b66\u7684\u30a2\u30c9\u30d0\u30a4\u30b9\u4f1a\u8b70\u304b\u3089\u3082\u80af\u5b9a\u7684\u306a\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u3092\u53d7\u3051\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-location\">\u30e8\u30fc\u30ed\u30c3\u30d1<\/span>.<\/p>\n<p class=\"prnml40\" style=\"padding-left: 40px;\">IMA \u306f\u3001MCO-010 \u6cbb\u7642\u5f8c\u306e\u5f31\u8996 RP \u60a3\u8005\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306e\u9069\u5207\u306a\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u8996\u529b\u3092\u627f\u8a8d\u3057\u307e\u3057\u305f\u3002<\/p>\n<p class=\"prnml40\" style=\"padding-left: 40px;\">IMA\u306f\u307e\u305f\u30010.3 logMAR\u306e\u5909\u5316\u306f\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931RP\u60a3\u8005\u306b\u3068\u3063\u3066\u81e8\u5e8a\u7684\u306b\u610f\u5473\u304c\u3042\u308b\u3068\u652f\u6301\u3057\u305f\u3002<\/p>\n<p class=\"prnml40\" style=\"padding-left: 40px;\">IMA \u306f\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u304c MCO-010 \u306e\u6761\u4ef6\u4ed8\u304d\u627f\u8a8d\u3092\u691c\u8a0e\u3059\u308b\u3053\u3068\u3092\u63d0\u6848\u3057\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-location\">\u30e8\u30fc\u30ed\u30c3\u30d1<\/span>\u00a0\u65e2\u5b58\u306e\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u3044\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u898f\u5236\u5f53\u5c40\u306e\u8b70\u8ad6\u306b\u57fa\u3065\u3044\u3066\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306f\u9032\u884c\u4e2d\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u3001\u4e8c\u91cd\u30de\u30b9\u30af\u3001\u591a\u65bd\u8a2d\u30d5\u30a7\u30fc\u30ba\u306e\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u8996\u529b\u306b\u623b\u308a\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u52c9\u5f37\uff08\u5fa9\u5143\uff09\u3057\u307e\u3059\u3002\u7814\u7a76\u7d42\u4e86\u6642\u306e 100 \u9031\u9593\u30c7\u30fc\u30bf\u306f 2024 \u5e74\u4e0a\u534a\u671f\u306b\u5831\u544a\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/p>\n<p>\u201c\u300cFDA\u3068IMA\u306e\u4e21\u65b9\u304b\u3089\u3001\u8996\u529b\u691c\u67fb\u3092\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3059\u308b\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066\u4e00\u8cab\u3057\u305f\u610f\u898b\u304c\u5f97\u3089\u308c\u305f\u3053\u3068\u306f\u3001Nanoscope\u306b\u3068\u3063\u3066\u5927\u304d\u306a\u7bc0\u76ee\u3067\u3042\u308a\u3001MCO-010\u306b\u7c73\u56fd\u304a\u3088\u3073\u30a4\u30f3\u30c9\u306b\u304a\u3051\u308b\u660e\u78ba\u306a\u898f\u5236\u4e0a\u306e\u9053\u7b4b\u3092\u63d0\u4f9b\u3059\u308b\u3082\u306e\u3067\u3059\u3002\u300d\u00a0<span class=\"xn-location\">\u30e8\u30fc\u30ed\u30c3\u30d1<\/span>,\u3001&quot; \u8a00\u3063\u305f\u00a0<span class=\"xn-person\">\u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4<\/span>\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u5171\u540c\u5275\u8a2d\u8005\u517cCEO\u3002<\/p>\n<p><b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306f\u3001\u7db2\u819c\u306e\u5149\u53d7\u5bb9\u7d30\u80de\u304c\u6642\u9593\u3068\u3068\u3082\u306b\u5909\u6027\u3057\u3001\u8996\u529b\u969c\u5bb3\u3084\u6700\u7d42\u7684\u306b\u306f\u5931\u660e\u306b\u81f3\u308b\u7a00\u306a\u907a\u4f1d\u6027\u75be\u60a3\u7fa4\u306e\u7dcf\u79f0\u3067\u3059\u3002\u3053\u308c\u3089\u306e\u75be\u60a3\u306f\u3001100\u7a2e\u985e\u4ee5\u4e0a\u306e\u907a\u4f1d\u5b50\u5909\u7570\u306b\u95a2\u9023\u3057\u3066\u3044\u308b\u3068\u8003\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u7c73\u56fd\u3067\u306f\u7d0410\u4e07\u4eba\u3001\u4e16\u754c\u3067\u306f\u63a8\u5b9a200\u4e07\u4eba\u304cRP\u306b\u7f79\u60a3\u3057\u3066\u304a\u308a\u3001\u907a\u4f1d\u6027\u5931\u660e\u306e\u4e3b\u306a\u539f\u56e0\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002.<\/p>\n<p><b>MCO-010\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u73fe\u5728\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u306f\u3001\u7279\u5b9a\u306e\u907a\u4f1d\u5b50\u5909\u7570\u3092\u6301\u3064\u60a3\u8005\u306e\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u308b\u304c\u3001\u7db2\u819c\u5916\u5c64\u7d30\u80de\u304c\u5909\u6027\u3057\u305f\u9032\u884c\u6027\u75be\u60a3\u3067\u306f\u3055\u3089\u306b\u9650\u754c\u304c\u3042\u308b\u3002\u5468\u56f2\u5149\u3067\u6d3b\u6027\u5316\u53ef\u80fd\u306a MCO \u5149\u907a\u4f1d\u5b66\u7684\u5358\u72ec\u7642\u6cd5\u306f\u3001\u8c4a\u5bcc\u306a\u7db2\u819c\u5185\u30cb\u30e5\u30fc\u30ed\u30f3\u3092\u6a19\u7684\u3068\u3057\u3001\u9032\u884c\u3057\u305f RP \u306b\u3088\u308a\u6c38\u4e45\u306b\u5931\u308f\u308c\u305f\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002 MCO-010 (sonpiretigene isteparvovec\u3001\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u7528\u61f8\u6fc1\u6db2) \u306f\u3001\u73fe\u5728\u81e8\u5e8a\u8a66\u9a13\u4e2d\u306e\u552f\u4e00\u306e\u5e83\u5e2f\u57df\u3001\u9ad8\u901f\u3001\u6700\u3082\u5149\u611f\u53d7\u6027\u306e\u9ad8\u3044\u30aa\u30d7\u30b7\u30f3\u3067\u3059\u3002 MCO-010 \u767a\u73fe\u30ab\u30bb\u30c3\u30c8\u306f\u3001mGluR6 \u30d7\u30ed\u30e2\u30fc\u30bf\u30fc\u30a8\u30f3\u30cf\u30f3\u30b5\u30fc\u3092\u4ecb\u3057\u305f\u53cc\u6975\u7d30\u80de\u30bf\u30fc\u30b2\u30c6\u30a3\u30f3\u30b0\u3092\u5099\u3048\u3001\u73fe\u5b9f\u4e16\u754c\u306e\u74b0\u5883\u3067\u9ad8\u54c1\u8cea\u306e\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u72ec\u81ea\u306e AAV2 \u30d9\u30af\u30bf\u30fc\u306b\u3088\u308a\u3001\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u306b\u3088\u308b\u53cc\u6975\u7d30\u80de\u3078\u306e MCO-010 \u306e\u5f37\u529b\u306a\u5f62\u8cea\u5c0e\u5165\u304c\u53ef\u80fd\u306b\u306a\u308a\u307e\u3059\u3002\u9032\u884cRP\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u306e\u7b2c1\/2\u76f8\u8a66\u9a13\u3067\u306f\u3001\u826f\u597d\u306a\u5b89\u5168\u6027\u3068\u7528\u91cf\u4f9d\u5b58\u7684\u306a\u8996\u529b\u306e\u6539\u5584\u304c\u5b9f\u8a3c\u3055\u308c\u307e\u3057\u305f\u3002 MCO-010\u6cbb\u7642\u3092\u53d7\u3051\u305f\u60a3\u8005\u3067\u306f\u3001\u5bfe\u7167\u7fa4\u3068\u6bd4\u8f03\u3057\u3066\u3001\u540d\u76ee\u4e0a\u6709\u610f\u306a\u8996\u529b\u306e\u6539\u5584\u304c\u89b3\u5bdf\u3055\u308c\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u5fa9\u5143\u30c8\u30e9\u30a4\u30a2\u30eb\u3002\u307e\u305f\u3001\u591a\u8f1d\u5ea6\u8996\u899a\u306b\u57fa\u3065\u304f\u53ef\u52d5\u6027\u3068\u5f62\u72b6\u8b58\u5225\u306b\u3088\u3063\u3066\u8a55\u4fa1\u3055\u308c\u308b\u3088\u3046\u306b\u3001\u540d\u76ee\u4e0a\u5927\u5e45\u306a\u6a5f\u80fd\u7684\u8996\u899a\u306e\u6539\u5584\u304c\u898b\u3089\u308c\u3001\u597d\u307e\u3057\u3044\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3082\u5f97\u3089\u308c\u307e\u3057\u305f\u3002<\/p>\n<p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306f\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306b\u5bfe\u3057\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u3002\u3053\u308c\u3089\u306e\u75be\u60a3\u306b\u306f\u6cbb\u7642\u6cd5\u304c\u5b58\u5728\u3057\u306a\u3044\u3002\u540c\u793e\u306e\u4e3b\u8981\u958b\u767a\u5019\u88dc\u3067\u3042\u308bMCO-010\u306f\u3001\u6700\u8fd1\u3001RESTORE\u30d5\u30a7\u30fc\u30ba\u306e\u4e3b\u8981\u7d50\u679c\u3092\u767a\u8868\u3057\u305f\u3002\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u7c73\u56fd\u306b\u304a\u3051\u308b\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308b\u591a\u65bd\u8a2d\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u30de\u30b9\u30af\u507d\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\uff08<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4071016-1&h=1764809894&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D4290035820%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3984630-1%2526h%253D517760235%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT04945772%25253Fterm%25253DNanoscope%252526draw%25253D2%2526a%253DNCT04945772%26a%3DNCT04945772&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09\u3002\u540c\u793e\u306f\u6700\u8fd1\u3001\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f MCO-010 \u7642\u6cd5\u306e\u7b2c 2 \u76f8 STARLIGHT \u8a66\u9a13\u3082\u5b8c\u4e86\u3057\u307e\u3057\u305f (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4071016-1&h=831375813&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D736901417%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3984630-1%2526h%253D1090222651%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT05417126%25253Fterm%25253Dnanoscope%252526draw%25253D2%252526rank%25253D3%2526a%253DNCT05417126%26a%3DNCT05417126&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\u00a0\uff09\u3002 MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u3068\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u306e\u4e21\u65b9\u306b\u5bfe\u3057\u3066FDA\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u304a\u3088\u3073FDA\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u8cc7\u7523\u306b\u306f\u3001\u5730\u7406\u7684\u840e\u7e2e\u306b\u5bfe\u3059\u308b\u975e\u30a6\u30a4\u30eb\u30b9\u30ec\u30fc\u30b6\u30fc\u306b\u3088\u308b MCO-020 \u907a\u4f1d\u5b50\u6cbb\u7642\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n<p><b>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b><br class=\"dnr\" \/>\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>FDA and EU Regulators provide consistent advice that visual acuity may serve as primary endpoint to evaluate the effectiveness of MCO-010 in the treatment of low-vision retinitis pigmentosa (RP) patients Regulatory feedback provides clarity for potential path to approval in the US and in\u00a0Europe\u00a0for MCO-010 in RP; Nanoscope preparing for immediate execution DALLAS,\u00a0Jan. 18, 2024 \u2014\u00a0Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (\u201cFDA\u201d) and from the Scientific Advice meeting with the Icelandic Medicines Agency (\u201cIMA\u201d), regarding the regulatory path of MCO-010 for [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5635,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5634","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-18T15:41:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:24:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa\",\"datePublished\":\"2024-01-18T15:41:56+00:00\",\"dateModified\":\"2025-06-27T16:24:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\"},\"wordCount\":722,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_regulatory-update.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\",\"name\":\"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_regulatory-update.jpg\",\"datePublished\":\"2024-01-18T15:41:56+00:00\",\"dateModified\":\"2025-06-27T16:24:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_regulatory-update.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_regulatory-update.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306b\u95a2\u3059\u308b\u898f\u5236\u5f53\u5c40\u306e\u6700\u65b0\u60c5\u5831\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-01-18T15:41:56+00:00","article_modified_time":"2025-06-27T16:24:42+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa","datePublished":"2024-01-18T15:41:56+00:00","dateModified":"2025-06-27T16:24:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/"},"wordCount":722,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","url":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306b\u95a2\u3059\u308b\u898f\u5236\u5f53\u5c40\u306e\u6700\u65b0\u60c5\u5831\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","datePublished":"2024-01-18T15:41:56+00:00","dateModified":"2025-06-27T16:24:42+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=5634"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5634\/revisions"}],"predecessor-version":[{"id":9058,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5634\/revisions\/9058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/5635"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=5634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=5634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=5634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}